Clinical Trials

Phase 3 Not yet recruiting

Breast Neoplasms

NCT07461454 2026-03-10

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

376 enrolled

Breast Neoplasms

NCT04468061 2026-02-27

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

110 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06100874 2026-02-24

A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)

28 enrolled

Breast Neoplasms

NCT06963905 2026-02-17

SIMONE

60 enrolled

Triple Negative Breast Neoplasms

NCT04639986 2026-02-09

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

331 enrolled

Breast Neoplasms

NCT04454437 2026-02-02

Study of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments

80 enrolled

Triple Negative Breast Neoplasms

NCT06926920 2026-01-30

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

100 enrolled

Triple Negative Breast Neoplasms

NCT07367178 2026-01-28

SATROPIN

30 enrolled

Breast Neoplasms

NCT07368543 2026-01-28

STORM

216 enrolled

Phase 2 Enrolling by invitation

Breast Neoplasms

NCT07359404 2026-01-22

Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC

60 enrolled

Advanced Breast Cancer

NCT05633654 2026-01-20

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Phase 3 Recruiting

1,514 enrolled

Triple Negative Breast Neoplasms

NCT04448886 2026-01-15

Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBC

110 enrolled 26 charts

Breast Neoplasms

NCT06263543 2025-12-26

SERIES

75 enrolled

Breast Neoplasms

NCT06238921 2025-12-05

Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases

31 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06612203 2025-12-05

WIN-B

76 enrolled

Advanced Breast Cancer

NCT05520723 2025-12-04

PRIMED

Phase 2 Completed

50 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT06409390 2025-12-04

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

15 enrolled

Breast Neoplasms

NCT04595565 2025-11-25

SASCIA

1,332 enrolled

Triple Negative Breast Neoplasms

NCT04986579 2025-11-19

Scalp Cooling in MBC

120 enrolled

Breast Neoplasms

NCT05867251 2025-11-19

Study of AVZO-021 in Patients With Advanced Solid Tumors

430 enrolled

BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT06081244 2025-11-19

ADAPT-TN-III

Phase 3 Recruiting

348 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04958785 2025-11-04

ELEVATE TNBC

Phase 2 Terminated

92 enrolled 27 charts

Triple Negative Breast Neoplasms

NCT05675579 2025-11-04

A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC)

27 enrolled

Breast Neoplasms

NCT07011654 2025-10-23

Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

31 enrolled

Triple Negative Breast Neoplasms

NCT04230109 2025-10-14

NeoSTAR

260 enrolled

Phase 1 Active not recruiting

Triple Negative Breast Neoplasms

NCT05143229 2025-10-06

ASSET

18 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT05840211 2025-10-03

ASCENT-07

654 enrolled

Breast Neoplasms

NCT06462092 2025-09-29

Sacituzumab Govitecan and Intrathecal Chemotherapy for Treating Leptomeningeal Metastases From Her2-negative Breast Cancer

34 enrolled

BreastCNS

Breast Neoplasms, Meningeal Carcinomatosis

NCT06827613 2025-09-24

START-002

50 enrolled

Phase 3 Not yet recruiting

Triple Negative Locally Advanced Non-resectable Breast Cancer

NCT07178730 2025-09-17

ADAPT-TN-IV

765 enrolled

Phase 1 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT07163481 2025-09-16

SoGreat

12 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT07040644 2025-09-08

A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC

150 enrolled

Triple Negative Breast Neoplasms

NCT05382299 2025-09-05

ASCENT-03

623 enrolled

Triple Negative Breast Neoplasms

NCT07151586 2025-09-03

ALTER

260 enrolled

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT04434040 2025-08-19

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

40 enrolled

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT07046455 2025-07-01

Trop-2 Targeted PET Probes in Advanced TNBC

Phase NA Recruiting

20 enrolled

Triple Negative Breast Neoplasms

NCT06665178 2025-06-25

Genomic and Transcriptomic Predictors of Sequential SG Sensitivity After T-DXd in ER+/HER2-Low Metastatic Breast Cancer

20 enrolled

Breast Neoplasms

NCT05552001 2025-06-11

ISIdE

Phase 3 Recruiting

96 enrolled

Breast Neoplasms, Neoplasm Metastasis, Triple Negative Breast Neoplasms

NCT03971409 2025-05-02

InCITe

150 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05770531 2025-04-04

Circulating Tumor DNA to Guide Changes in Standard of Care Chemotherapy

160 enrolled

Phase 1/2 Active not recruiting

Triple Negative Breast Neoplasms

NCT05101096 2025-03-25

ASCENT-J02

135 enrolled

Triple Negative Breast Neoplasms

NCT05332561 2025-03-20

Genomics Guided Targeted Post-neoadjuvant Therapy in Patients With Early Breast Cancer (COGNITION-GUIDE)

240 enrolled

Breast Neoplasms

NCT05113966 2025-01-29

Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer

Phase 2 Terminated

30 enrolled 16 charts

Triple Negative Breast Neoplasms

NCT06102824 2024-11-25

ORIENTA

252 enrolled

543 enrolled 25 charts 1 FDA

HER2-negative Breast Cancer

NCT03901339 2024-10-21

TROPiCS-02

Phase 3 Completed

Breast Neoplasms

NCT06236269 2024-07-19

ACROSS-TROP2

50 enrolled

Breast Neoplasms

NCT06462079 2024-06-17

Sacituzumab Govitecan Combined With Head Radiotherapy for Her2-negative Breast Cancer Brain Metastases

43 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT06328387 2024-03-25

HCQ+ADC vs ADC in the Treatment of Advanced Breast Cancer

120 enrolled